Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma

References

• Hidalgo M, Cascinu S, Kleeff J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15:8–18.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review. Bethesda, MD: National Cancer Institute; 1975–2013 [cited based on November 2015 SEER data submission posted to the SEER web site, April 2016]. Available from: http://seer.cancer.gov/csr/1975_2013/.
   Google Scholar
• Carrato A, Falcone A, Ducreux M, et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 2015;46:201–211.
   PubMedGoogle Scholar
• Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3:105–119.
   PubMedGoogle Scholar
• Firpo MA, Boucher KM, Mulvihill SJ. Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers. Theor Biol Med Model. 2014;11:34.
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Koldobskiy MA, Göndör A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17:284–299.
   PubMed Web of Science ®Google Scholar
• Tan AC, Jimeno A, Lin SH, et al. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol. 2009;3:425–438.
   PubMed Web of Science ®Google Scholar
• Hinton J, Callan R, Bodine C, et al. Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas. Expert Rev Mol Diagn. 2013;13:431–443.
   PubMed Web of Science ®Google Scholar
• Omura N, Li C-P, Li A, et al. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther. 2008;7:1146–1156.
   PubMed Web of Science ®Google Scholar
• Nones K, Waddell N, Song S, et al. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer. 2014;135:1110–1118.
   PubMed Web of Science ®Google Scholar
• Li A, Omura N, Hong S-M, et al. Epigenetic silencing of transcription factor SIP1 in pancreatic cancer cells is associated with elevated expression and blood serum levels of microRNAs miR-200a,b. Cancer Res. 2010;70:5226–5237.
   Google Scholar
• Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000;28:E32e.
   Web of Science ®Google Scholar
• Akey DT, Akey JM, Zhang K, et al. Assaying DNA methylation based on high-throughput melting curve approaches. Genomics. 2002;80:376–384.
   PubMed Web of Science ®Google Scholar
• Gitan RS, Shi H, Chen C-M, et al. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res. 2002;12:158–164.
   PubMed Web of Science ®Google Scholar
• Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 2006;16:383–393.
   PubMed Web of Science ®Google Scholar
• Dirks RAM, Stunnenberg HG, Marks H. Genome-wide epigenomic profiling for biomarker discovery. Clin Epigenet. 2016;8:122.
   PubMed Web of Science ®Google Scholar
• Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A. 1992;89:1827–1831.
   PubMed Web of Science ®Google Scholar
• Herman JG, Graff JR, Myöhänen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821–9826.
   PubMed Web of Science ®Google Scholar
• Giacona MB, Ruben GC, Iczkowski KA, et al. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998;17:89–97.
   PubMed Web of Science ®Google Scholar
• Shapiro B, Chakrabarty M, Cohn EM, et al. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983;51:2116–2120.
   PubMed Web of Science ®Google Scholar
• Volik S, Alcaide M, Morin RD, et al. Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging technologies. Mol Cancer Res. 2016;14:898–908.
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–1665.
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Higashi M, Kitamoto S, et al. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas. Oncotarget. 2016;7:42553–42565.
   PubMed Web of Science ®Google Scholar
• Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4:45–60.
   PubMed Web of Science ®Google Scholar
• Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int. 1997;47:813–830.
   PubMed Web of Science ®Google Scholar
• Yamada N, Nishida Y, Tsutsumida H, et al. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res. 2008;68:2708–2716.
   PubMed Web of Science ®Google Scholar
• Yamada N, Hamada T, Goto M, et al. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer. 2006;119:1850–1857.
   PubMed Web of Science ®Google Scholar
• Ho JJ, Han SW, Pan PL, et al. Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells. Int J Oncol. 2003;22:273–279.
   PubMed Web of Science ®Google Scholar
• Kitamoto S, Yamada N, Yokoyama S, et al. Promoter hypomethylation contributes to the expression of MUC3A in cancer cells. Biochem Biophys Res Commun. 2010;397:333–339.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang J-j, Zhu R, et al. The increase in the expression and hypomethylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma. Med Oncol. 2011;28:175–184.
   PubMed Web of Science ®Google Scholar
• Yamada N, Nishida Y, Yokoyama S, et al. Expression of MUC5AC, an early marker of pancreatobiliary cancer, is regulated by DNA methylation in the distal promoter region in cancer cells. J Hepatobiliary Pancreat Sci. 2010;17:844–854.
   PubMed Web of Science ®Google Scholar
• Kitamoto S, Yamada N, Yokoyama S, et al. DNA methylation and histone H3-K9 modifications contribute to MUC17 expression. Glycobiology. 2011;21:247–256.
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Kitamoto S, Higashi M, et al. Diagnosis of pancreatic neoplasms using a novel method of DNA methylation analysis of mucin expression in pancreatic juice. PLoS One. 2014;9:e93760.
   PubMed Web of Science ®Google Scholar
• Botezatu A, Bleotu C, Nastase A, et al. Epigenetic silencing of GNMT gene in pancreatic adenocarcinoma. Cancer Genomics Proteom. 2015;12:21–30.
   PubMed Web of Science ®Google Scholar
• Yi JM, Guzzetta AA, Bailey VJ, et al. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 2013;19:6544–6555.
   PubMed Web of Science ®Google Scholar
• Matsubayashi H, Sato N, Fukushima N, et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res. 2003;9:1446–1452.
   PubMed Web of Science ®Google Scholar
• Okami J, Simeone DM, Logsdon CD. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res. 2004;64:5338–5346.
   PubMed Web of Science ®Google Scholar
• Ueki T, Toyota M, Skinner H, et al. Identification and characterization of differentially methylated CpG Islands in pancreatic carcinoma. Cancer Res. 2001;61:8540–8546.
   PubMed Web of Science ®Google Scholar
• Sato N, Fukushima N, Maehara N, et al. SPARC//osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003;22:5021–5030.
   PubMed Web of Science ®Google Scholar
• Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 2003;63:4158.
   PubMed Web of Science ®Google Scholar
• Pedersen KS, Bamlet WR, Oberg AL, et al. Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS One. 2011;6:e18223.
   PubMed Web of Science ®Google Scholar
• Zhang S, Hao J, Xie F, et al. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis. 2011;32:1183–1189.
   PubMed Web of Science ®Google Scholar
• Vogt M, Munding J, Grüner M, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 2011;458:313–322.
   PubMed Web of Science ®Google Scholar
• Li M, Fang Y. Histone variants: the artists of eukaryotic chromatin. Sci China Life Sci. 2015;58:232–239.
   PubMed Web of Science ®Google Scholar
• Ma F, Zhang CY. Histone modifying enzymes: novel disease biomarkers and assay development. Expert Rev Mol Diagn. 2016;16:297–306.
   PubMed Web of Science ®Google Scholar
• Neureiter D, Jäger T, Ocker M, et al. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol. 2014;20:7830–7848.
   PubMed Web of Science ®Google Scholar
• Huang B, Jiang C, Zhang R. Epigenetics: the language of the cell?. Epigenomics. 2014;6:73–88.
   PubMed Web of Science ®Google Scholar
• Aghdassi A, Sendler M, Guenther A, et al. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut. 2012;61:439–448.
   PubMed Web of Science ®Google Scholar
• Hong SM, Li A, Olino K, et al. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod Pathol. 2011;24:1237–1247.
   PubMed Web of Science ®Google Scholar
• Chen J, Xu H, Zou X, et al. Snail recruits ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells. Cancer Res. 2014;74:4353–4363.
   PubMed Web of Science ®Google Scholar
• Wiles ET, Selker EU. H3K27 methylation: a promiscuous repressive chromatin mark. Curr Opin Genet Dev. 2017;43:31–37.
   PubMed Web of Science ®Google Scholar
• Wei Y, Xia W, Zhang Z, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008;47:701–706.
   PubMed Web of Science ®Google Scholar
• Manuyakorn A, Paulus R, Farrell J, et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. JCO. 2010;28:1358–1365.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Morinaga S, Akaike M, et al. The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery. Eur J Surg Oncol. 2012;38:1051–1057.
   PubMed Web of Science ®Google Scholar
• Bauden M, Pamart D, Ansari D, et al. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clin Epigenet. 2015;7:106.
   PubMed Web of Science ®Google Scholar
• Diab M, Muqbil I, Mohammad RM, et al. The role of microRNAs in the diagnosis and treatment of pancreatic adenocarcinoma. JCM. 2016;5:59.
   Web of Science ®Google Scholar
• Liu J, Gao J, Du Y, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer. 2012;131:683–691.
   PubMed Web of Science ®Google Scholar
• Abue M, Yokoyama M, Shibuya RIE, et al. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol. 2015;46:539–547.
   PubMed Web of Science ®Google Scholar
• Szafranska-Schwarzbach AE, Adai AT, Lee LS, et al. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma. Expert Rev Mol Diagn. 2011;11:249–257.
   PubMed Web of Science ®Google Scholar
• Yang J-Y, Sun Y-W, Liu D-J, et al. MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. Am J Cancer Res. 2014;4:663–673.
   PubMed Web of Science ®Google Scholar
• Visani M, Acquaviva G, Fiorino S, et al. Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. J Clin Pathol. 2015;68:859–869.
   PubMed Web of Science ®Google Scholar